Veru (VERU) Change in Receivables (2015 - 2024)
Veru (VERU) posted quarterly Change in Receivables of $657253.0 for Q4 2024, up 130.95% year-over-year from $284586.3 in Q1 2024, and down 71.65% quarter-over-quarter from $2.3 million in Q3 2024.
Veru (VERU) Change in Receivables (2015 - 2024) Analysis & Trends
Veru (VERU) has reported Change in Receivables for 10 consecutive years, with $657253.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Change in Receivables rose 130.95% year-over-year to $657253.0; the TTM figure through Sep 2025 stood at $657253.0 (up 220.33% YoY), while the FY2025 annual figure was $657253.0, up 220.33% from the prior year.
- Change in Receivables fell to $657253.0 in Q4 2024 per VERU's latest filing, from $2.3 million in the prior quarter.
- Across five years, Change in Receivables topped out at $4.3 million in Q1 2023 and bottomed at -$5.5 million in Q3 2022.
- Historically, Change in Receivables has averaged $136678.0 across 5 years, with a median of $342327.5 in 2020.
- Annual changes were most pronounced in 2020 — Change in Receivables soared 2087.45% — and 2022, when it tumbled 1242.27%.
- Veru's Change in Receivables stood at -$1.1 million in 2020, then soared by 32.36% to -$724683.0 in 2021, then soared by 44.72% to -$400585.0 in 2022, then plunged by 430.12% to -$2.1 million in 2023, then jumped by 130.95% to $657253.0 in 2024.
- Business Quant data shows VERU's Change in Receivables at $657253.0 in Q4 2024, $2.3 million in Q3 2024, and -$1.1 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 657,253.00 |
| Dec 31, 2024 | 657,253.00 |
| Sep 30, 2024 | 2.32 Mn |
| Sep 30, 2024 | 2.32 Mn |
| Jun 30, 2024 | -1.14 Mn |
| Jun 30, 2024 | -1.14 Mn |
| Mar 31, 2024 | 402,394.00 |
| Mar 31, 2024 | 402,394.00 |
| Dec 31, 2023 | -2.12 Mn |
| Dec 31, 2023 | -2.12 Mn |
| Sep 30, 2023 | -576,370.00 |
| Sep 30, 2023 | -576,370.00 |
| Jun 30, 2023 | 876,911.00 |
| Jun 30, 2023 | 876,911.00 |
| Mar 31, 2023 | 4.25 Mn |
| Mar 31, 2023 | 4.25 Mn |
| Dec 31, 2022 | -400,585.00 |
| Dec 31, 2022 | -400,585.00 |
| Sep 30, 2022 | -5.47 Mn |
| Sep 30, 2022 | -5.47 Mn |